PHARMACY BENEFITS MANAGEMENT SERVICES (PBM)
ID: 1605C3-24-R-00011Type: Solicitation
Overview

Buyer

LABOR, DEPARTMENT OFOFFICE OF THE ASSISTANT SECRETARY FOR ADMINISTRATION AND MANAGEMENTDOL - CAS DIVISION 3 PROCUREMENTWASHINGTON, DC, 20210, USA

NAICS

Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds (524292)

PSC

SOCIAL- GOVERNMENT INSURANCE PROGRAMS: OTHER (G008)
Timeline
    Description

    The Department of Labor (DOL) is seeking proposals for Pharmacy Benefits Management (PBM) Services on behalf of the Office of Workers' Compensation Programs (OWCP). The procurement aims to establish a single award fixed-price contract to provide comprehensive PBM services, including the management of prescription drugs, durable medical equipment, and diagnostic services for various compensation programs. This initiative is crucial for ensuring effective oversight of pharmacy benefits, enhancing patient care, and maintaining compliance with federal regulations. Interested vendors must submit their proposals by January 21, 2025, and can direct inquiries to Broderick Morris or Helen A. Williams via their respective emails.

    Point(s) of Contact
    Broderick Morris
    Morris.Broderick@DOL.Gov
    Helen A. Williams
    williams.helen.a@dol.gov
    Files
    Title
    Posted
    The "Past Performance Questionnaire" is a form designed for contractors submitting proposals to the Department of Labor (DOL) as part of federal RFPs and grants. Its purpose is to evaluate the past performance of contractors through structured ratings across several key areas: Quality of Services, Cost Control, Schedule/Timeliness, Management/Business Relations, Small Business Subcontracting, and Regulatory Compliance. Each category utilizes a standardized rating scale from "Exceptional" to "Unsatisfactory," assessing the contractor's effectiveness and overall performance, while allowing for comments and justifications for ratings given. Additionally, the form concludes with an overall performance rating and a question regarding the potential for future business. This systematic approach aims to ensure accountability and quality in government contracting, highlighting the importance of past performance in assessing contractor reliability and proficiency. By focusing on past experiences, the questionnaire supports informed decision-making for potential future contracts.
    The file presents detailed records of prescription medications prescribed and dispensed across various states, including Maryland, Alabama, Pennsylvania, and Florida. It includes information on case numbers, pharmacy numbers, prescription numbers, prescriber DEA numbers, dates of service, National Drug Codes (NDC), drug descriptions, whether the medication was a compound, and the quantity prescribed. The data spans numerous entries detailing prescriptions like acetaminophen/hydrocodone combinations, antidepressants, and pain management medications, with varying quantities indicating the scale of prescriptions issued. The document serves as a database for tracking medication prescriptions, potentially useful for assessing healthcare compliance, prescribing patterns, and facilitating audits in relation to federal and state regulations. Its design conveys a systematic appending of patient and prescription data, reflecting the need for regulatory oversight in pharmaceutical distribution and usage within government healthcare programs.
    The document outlines the specifications for a Pharmacy Benefit Manager (PBM) to effectively display various required data elements within the Office of Workers' Compensation Programs (OWCP) staff portal. It lists critical information, including case details (case number, claimant information), eligibility specifics (date of injury, accepted conditions), and medical transaction data (medication details, prescriber information, claim statuses). Additionally, it specifies requirements for displaying prescription information, including transaction status, payments, and various codes related to the medication and service rendered. The comprehensive list serves to ensure that relevant stakeholders have access to vital information necessary for processing claims and managing cases effectively. This specification is part of broader federal RFPs and grants aimed at streamlining healthcare and compensation services, enhancing operational efficiency, and ensuring compliance with relevant regulations. The document clearly indicates the critical nature of accurate data representation in managing and adjudicating workers' compensation claims within the federal framework.
    The document outlines various guidelines and parameters related to the management and coverage of medications, specifically opioids, in the context of federal and state healthcare programs. It incorporates references to specific Generic Product Identifiers (GPI) such as GPI-2, GPI-6, and GPI-14, detailing their descriptions and formulary types, including the classification of drugs as SA/LA opioids. The document emphasizes compliance with FDA indications, relevant maintenance indicators, and historical transaction data while aligning with Official Disability Guidelines (ODG) and other nationally recognized frameworks. It specifies coverage summaries, including step therapy requirements, prior authorization conditions, and limits on quantity, costs, and frequency of medication fill for patient claims. The core purpose of this information appears to be the standardization and regulation of opioid prescriptions to enhance patient safety, optimize healthcare spending, and ensure adherence to established guidelines in governmental healthcare programs.
    The document outlines a pricing structure for specific medications under a full pass-through pricing model within a government context, detailing costs associated with ibuprofen, lexapro, and ofev over a 30-day supply. It presents various pricing scenarios based on pharmacy submitted prices, OWCP fee schedules, U&C rates, maximum allowable costs, AWP discounts, and final billed amounts to the government. Key figures indicate ingredient and dispensing fees across different tiers, highlighting the lowest price cost basis and the final amounts due after applicable service fees and rebates. Overall, this detailed cost analysis serves to ensure transparent pricing and compliance within federal and state drug reimbursement frameworks, playing a significant role in healthcare funding and spending oversight within government RFPs and grants.
    The document outlines various aspects of government requests for proposals (RFPs), federal grants, and state and local procurements. It emphasizes the importance of structured methodologies and compliance with regulations during the proposal process. Key topics include the need for documentation, the role of public notification for proposals, and the criteria for evaluating submissions, which often involve detailed assessments of qualifications, past experiences, and pricing. The material highlights that proposals should clearly align with project goals and ensure transparency as well as accountability throughout the procurement process. Additionally, the impact of compliance with federal guidelines and local policies is discussed, underlining the significance of these processes in supporting public sector projects and enhancing service delivery to communities. In effect, the document serves as a practical guide for stakeholders involved in crafting and submitting proposals for government-funded projects, aiming to enhance effectiveness and ensure adherence to necessary standards.
    The Office of Workers' Compensation Programs (OWCP) has developed an Award Term Incentive Plan to establish guidelines for evaluating contractor performance in delivering medical provider network and processing services. This plan aims to incentivize contractors to achieve successful project implementation, thereby extending contract performance periods beyond the initial base period for those demonstrating satisfactory performance. The plan identifies key performance areas, evaluation criteria, and responsibilities of the Award Term Review Team (ATRT), which assesses contractor capabilities based on specific factors. Performance is measured through a grading scale ranging from "Excellent" to "Unsatisfactory," with an emphasis on both technical and business management performance. The ATRT conducts ongoing progress reviews, ultimately deciding on award term eligibility based on evaluations conducted 45 to 60 days post-project go-live. The plan underscores collaboration between performance monitors and contractors, ensuring transparent communication regarding performance expectations and potential areas for improvement. The overarching goal is to enhance service delivery within the OWCP while prioritizing accountability and high-performance standards.
    The document outlines the Small Business Subcontracting Plan Template for the Pharmacy Benefits Management Services contract (RFP/Contract No: 1605C3-24-R-00011). It details the total dollar value of the contract, including base and option periods, and specifies the subcontracting goals across various categories of small businesses. The plan mandates a 60% allocation to small businesses, with additional percentages designated for small disadvantaged, women-owned, HUBZone, veteran-owned, and service-disabled veteran-owned small businesses. Each category’s percentage is consistent across contract terms. The document emphasizes that subcontract dollars may overlap across categories, allowing flexibility in accounting. Accurate documentation and calculation are vital to ensure compliance with federal regulations concerning small business participation. This plan underscores the government’s commitment to promoting small businesses in federal contracting opportunities.
    The document addresses Pharmacy Benefits Management Services (PBM) related to federal and state RFPs and grants. The main purpose is to solicit information or proposals from entities capable of providing effective management and oversight of pharmacy benefits for government programs. Key points include the importance of cost control, the need for transparency in drug pricing, and the provision of comprehensive services that encompass prescription drug management, utilization review, and patient safety assessments. Furthermore, the document emphasizes the integration of technological solutions to streamline operations and improve accessibility to medications for beneficiaries. Another critical aspect is compliance with federal regulations and guidelines, ensuring that the PBM services align with the overarching goals of government health initiatives. Through this RFP, the government aims to identify potential partners that can deliver efficient pharmacy management solutions while ensuring accountability and enhancing the overall quality of care for participants in these programs. This initiative reflects the government's commitment to optimizing healthcare services through strategic procurement and management practices.
    The document serves as a guide for offerors participating in the government's procurement process, specifically focusing on the submission of discounts, rebates, and service fees in an Excel workbook format. It outlines the purpose of the workbook, which includes displaying projections of financial impacts of discounts and rebates over various option periods. Offerors are instructed to input discount percentages as negative values and provide details on rebates and service fees with clear formatting guidelines. The base period and subsequent option periods detail various drug classes and associated financial figures, emphasizing transparency and accuracy in pricing proposals. Moreover, the workbook categorizes data into discount CLINS (Contract Line Item Numbers) and rebate CLINS for several drug types, alongside a service fee per transaction section. Key projections are based on historical data and provide an extensive cost breakdown for both the baseline and selected options. The document highlights critical financial components necessary for evaluating proposals, ensuring that the government can assess cost-effectiveness and compliance with established pricing models. This structured approach reinforces the importance of detailed pricing input for prospective contractors in government bidding processes.
    The file outlines instructions for offerors involved in federal pricing proposals regarding discounts, rebates, and service fees for various pharmaceuticals and medical services. Its primary goal is to help offerors report accurate pricing and discount structures to improve transparency during evaluation by government entities. Key components include the clarification of discount percentages, rebate amounts, and service fees, which must be inputted in specific sections of the provided Excel workbook. Offerors must denote discounts as negative figures and service fees as positive values, based on historical pricing models. The workbook includes separate tabs for different pricing categories: brand name retail drugs, generics, compounded drugs, specialty drugs, durable medical equipment (DME), and diagnostic services. The document also emphasizes the need for accuracy in submitted pricing and requires offerors to understand the government’s evaluation process, including projections of total evaluated prices by option periods. The detailed ongoing assessments during the base and option periods guide submission expectations ensuring compliance and competitive pricing in federal contracts, thus supporting informed decision-making in government procurement processes.
    The Performance Requirements Summary outlines the essential objectives, standards, and deliverables for a contractor engaged with the Department of Labor (DOL). It details specific performance thresholds required for various service aspects, emphasizing zero deviation from standards across all metrics, which is critical for mission success. Key areas of focus include enhanced quality control, continuous operation of systems, security requirements, background investigations, and customer support. The document lists submission timelines for essential documents, such as security plans and training, as well as requirements for maintaining operational integrity, such as the timely return of government-furnished equipment and compliance with fraud prevention measures. It also mandates the establishment of a pharmacy network, provision of medical services, and efficient claims processing, ensuring that claimants have access to necessary medical resources. The structured approach further specifies inspection methods, primarily via 100% oversight by designated Contracting Officer Representatives (COR) and project management teams, ensuring accountability and performance monitoring. This meticulous documentation serves as a framework for contractors to align their services with DOL expectations, fulfilling statutory obligations while delivering comprehensive healthcare support to claims under the OWCP.
    The document outlines a comprehensive Deliverables Schedule as part of a federal contract, detailing the timeline and submission requirements for various deliverables related to performance work statements (PWS). Key deliverables include developing a quality control plan, reporting delays, implementing a system security plan, maintaining security documentation, and providing necessary information for pharmacy networks. Each deliverable includes specific due dates (ranging from immediate to several months post-contract initiation) and formats for submission, primarily electronic, to designated oversight recipients such as the Contracting Officer (COR) and the Project Management Office (PMO). The purpose of this schedule is to ensure consistent, timely, and accurate reporting and documentation of activities and compliance with security and operational standards, essential for the effective management of contract responsibilities. The document emphasizes accountability and the need for rigorous documentation due to the complexities involved in federal procurement processes. Overall, it serves as a roadmap for contract performance and oversight in the context of government RFPs and grants, ensuring that all parties are aligned on expectations and timelines for deliverables.
    The document consists of numerous unique identification codes—primarily UUIDs—listed in a structured format without apparent contextual details. These codes likely correspond to various federal and state/local government RFPs (Requests for Proposals) and grants, potentially signifying distinct projects or initiatives eligible for funding or proposals. Each item, marked with a consistent numerical format, can be interpreted as a line item within a larger system of documentation related to government funding opportunities. The absence of descriptive text or linked information in the document limits the ability to ascertain specific topics or key ideas. The primary purpose appears to center around cataloging or indexing potential government engagements or funding sources without detailed elaboration on project aims, funding amounts, or application criteria. This structure indicates that it may serve as a preliminary reference for agencies or entities interested in government funding opportunities, suggesting a need for further inquiry into each code mentioned for detailed information related to specific proposals or grants. Overall, this document should be viewed as a foundational reference point rather than a comprehensive overview.
    The document outlines the federal government’s processes regarding Requests for Proposals (RFPs) and grants at both federal and state/local levels. It emphasizes the necessity for agencies to solicit bids for projects that meet specific funding criteria and project parameters. Central themes include the importance of transparency in the bidding process, equitable opportunity for all vendors, and adherence to regulatory requirements. The framework for issuing RFPs includes detailed guidelines to ensure competitive pricing, quality, and efficient project completion. Specifically, the document addresses how grants are awarded, the stipulations for compliance, and the importance of proposals that are financially viable and sustainable. Evaluators will look for thorough responses that demonstrate a clear understanding of project goals and the capacity to fulfill them. Furthermore, it underscores the necessity for governmental accountability and monitoring during implementation, to ensure that public funds are being utilized effectively. In summary, the document serves as a guideline to streamline the RFP and grant processes, fostering a competitive environment while upholding standards essential for public sector projects.
    The document outlines a Request for Proposal (RFP) for comprehensive Pharmacy Benefits Management (PBM) services by the U.S. Department of Labor's Office of Workers' Compensation Programs (OWCP). The aim is to establish a fixed-price contract to provide PBM services, including prescription drugs, durable medical equipment, and diagnostic services for the BLACK LUNG, ENERGY, FECA, and LONGSHORE programs. It specifies a performance period from April 25, 2025, to July 24, 2026, with four optional extensions and an award term. The RFP details the evaluation and management processes for proposals, emphasizing the importance of quality control, service efficiency, and compliance with federal regulations. Contractors are expected to maintain a workforce capable of meeting operational demands, providing both in-house and subcontracted services, and ensuring 24/7 service availability, including a continuity of operations plan. Key personnel qualifications are emphasized, including requirements for the program manager, pharmacists, and technical support roles. Moreover, the document lays out the necessity for addressing issues of fraud, waste, and abuse, alongside clear communication strategies with stakeholders. The RFP is vital for maintaining high standards in pharmaceutical benefit services for the affected workers under the OWCP's jurisdiction.
    This document outlines a Request for Proposals (RFP) regarding Pharmacy Benefits Management Services (PBM) and highlights key requirements and clarifications necessary for potential offerors. The RFP emphasizes the need for contractors to demonstrate understanding, risk mitigation, and compliance with various technical requirements. Crucial sections include discrepancies in referenced parts of the RFP, particularly in personnel qualifications and technical subfactors between Sections L and M. Additionally, the document provides detailed expectations for processing claims, medication use evaluations, and handling complicated cases involving state programs, as well as stipulations for record-keeping and reporting standards. Clarifications are provided on uploading eligibility files, billing methodologies, and adherence to coding standards, with a focus on pass-through pricing for pharmacy reimbursements. Key points include the necessity of audits for accurate classification, the establishment of the contractor’s clinical pharmacist roles, and the provision of an interactive web portal for claimant engagement. The government underlines the importance of developing comprehensive operational procedures, addressing claims from Black Lung claimants, and ensuring effective communication channels between all parties involved. This RFP aims to enhance the delivery of pharmacy benefits in compliance with federal guidelines while ensuring transparency and accountability.
    The document outlines a Request for Proposal (RFP) for Pharmacy Benefits Management (PBM) Services for the U.S. Department of Labor's Office of Workers' Compensation Programs (OWCP). The RFP anticipates a fixed-price contract with delivery due 365 days after award. It emphasizes the provision of comprehensive PBM services, including prescription drugs, durable medical equipment (DME), and diagnostic services for various compensation programs. The contractor’s responsibilities, including quality control, security, and personnel requirements, are detailed, highlighting the need for a robust transition-in/out plan to ensure continuity of services. Key objectives include reducing healthcare costs, enhancing patient care, and ensuring compliance with federal regulations. The contractor is required to facilitate the management of pharmacy benefits, provide oversight on medication utilization, and support new service integrations, aiming for improved healthcare outcomes. The performance is structured in phases with specific milestones, including rigorous documentation and communication protocols. The document emphasizes the importance of compliance and quality assurance in all aspects of service delivery, aiming to protect the interests of claimants and the federal government.
    Lifecycle
    Title
    Type
    Solicitation
    Similar Opportunities
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Active
    Dept Of Defense
    The Department of Defense (DoD) is seeking quotes for a Blanket Purchase Agreement (BPA) and Additional Discount Program (ADP) related to the procurement of pharmaceutical agents as part of its Uniform Formulary (UF) initiative. This procurement aims to establish an effective and integrated pharmacy benefits program for the Military Health System (MHS), focusing on the clinical and cost-effectiveness of newly approved drugs, including neurological agents, antibiotics, oncological agents, and various other pharmaceutical categories. Interested manufacturers must submit their quotes by January 16, 2025, with a pre-quotation teleconference scheduled for January 8, 2025, to discuss the requirements and expectations. For further inquiries, manufacturers can contact Tracy Banks at tracy.e.banks2.civ@health.mil or Patricia Tyson at patricia.a.tyson3.ctr@health.mil.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency, is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at establishing an effective pharmacy benefits program for the Military Health System. This procurement involves the evaluation and selection of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on newly approved drugs that will be reviewed by the Pharmacy and Therapeutics Committee in February 2025. Interested vendors must submit their pricing information, including National Drug Codes (NDCs), by December 19, 2024, and are encouraged to participate in a pre-quotation teleconference on December 4, 2024. For further inquiries, vendors can contact Tracy Banks at tracy.e.banks2.civ@mail.mil or Julia Trang at julia.n.trang.civ@health.mil.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency (DHA), is soliciting quotations for pharmaceutical agents to be included in the Uniform Formulary (UF) as part of its pharmacy benefits program for the Military Health System (MHS). This procurement aims to establish Blanket Purchase Agreements (BPAs) and Additional Discount Programs (ADPs) for cost-effective pharmaceutical options, ensuring that the selected agents meet clinical and cost-effectiveness criteria as evaluated by the Pharmacy and Therapeutics (P&T) Committee. The initiative is critical for providing safe and effective medications to military beneficiaries while managing costs within the healthcare system. Interested manufacturers must submit their quotes by December 30, 2024, and can direct inquiries to Tracy Banks or Keith Marasigan via their respective emails for further information.
    6505--Cyclobenzaprine Tablets (VA-25-00015093)
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Cyclobenzaprine HCL Tablets under solicitation number 36E79725R0009. This unrestricted procurement aims to secure a reliable supply of these essential pharmaceuticals for the VA, Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC), reflecting the government's commitment to providing necessary medications to veterans and associated healthcare systems. The contract will have an initial duration of one year, with the possibility of four additional one-year extensions, and interested vendors must provide specific drug labeling along with a unique National Drug Code (NDC). The RFP is expected to be released electronically around December 20, 2024, with a submission deadline set for January 3, 2025. For further inquiries, interested parties can contact Kenneth Lay at Kenneth.Lay@va.gov or by phone at 708-786-4879.
    Q517--Staffing Service MbM
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking proposals for staffing services under the Meds by Mail (MbM) program, specifically targeting Service-Disabled Veteran-Owned Small Businesses (SDVOSB). The procurement aims to provide licensed pharmacists and certified pharmacy technicians to support prescription processing across three facilities located in Cheyenne, WY; Dublin, GA; and Murfreesboro, TN. This initiative is crucial for enhancing healthcare services for veterans, ensuring efficient medication management and compliance with established protocols. Interested vendors must submit their proposals by the newly established deadline of August 6, 2024, with a total contract value estimated at $100 million over five years, including a minimum guarantee of $2 million. For further inquiries, potential bidders can contact Nicholas L. Schulte at nicholas.schulte1@va.gov or Christy Pendlay at Christy.Pendlay@va.gov.
    Norgestimate/Ethinyl Estradiol Tablets
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is soliciting offers for the supply of Norgestimate/Ethinyl Estradiol Tablets, a pharmaceutical product essential for oral contraceptive use. The procurement aims to establish a contract that outlines specific supply requirements, estimated quantities for multiple option years, and compliance with federal regulations, including ethical conduct and labor standards. This solicitation is critical for ensuring the availability of these contraceptive medications to support military personnel and their families. Interested contractors must submit their offers via the Defense Logistics Agency Internet Bid Board System (DIBBS) by January 21, 2025, and are encouraged to contact Kyle Lewicki at kyle.lewicki@dla.mil or Jason C. Wray at Jason.Wray@dla.mil for further information.
    Doxycycline Hyclate Solicitation
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the procurement of Doxycycline Hyclate tablets under solicitation number SPE2D2-25-R-0004. This procurement aims to secure pharmaceutical products in various quantities and packaging configurations, with specific requirements outlined for compliance with federal regulations, including business ethics and subcontracting plans. Doxycycline Hyclate is a critical antibiotic used in various medical applications, making this procurement essential for maintaining adequate supplies for military and healthcare operations. Interested contractors must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) by January 21, 2025, and are encouraged to contact Courtney Hunter-Stangler or Jason C. Wray for further information regarding the solicitation.
    Lamotrigine
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the procurement of various dosages of Lamotrigine ER, a pharmaceutical product. This solicitation (SPE2D2-25-R-0002) outlines the submission procedures for interested contractors, emphasizing the requirement for electronic submissions via the Defense Logistics Agency Internet Bid Board System (DIBBS) by the deadline of January 9, 2025. Lamotrigine is a critical medication used in the treatment of epilepsy and bipolar disorder, making this procurement essential for maintaining adequate supplies for military and healthcare facilities. For further inquiries, interested parties can contact Nancy Fernandez at nancy.fernandez@dla.mil or Jason C. Wray at Jason.Wray@dla.mil.
    6505--Carbidopa/Levodopa SA Tablet
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) intends to issue a Request for Proposal (RFP) 36E79725R0008 for the procurement of Carbidopa/Levodopa sustained release (SA) tablets, aimed at ensuring a continuous supply of these medications for various federal health services, including the Department of Defense and the Bureau of Prisons. The contract will be awarded for an initial period of one year, with the option to extend for four additional one-year periods, requiring offerors to provide unique branding and packaging without overlapping labels. The estimated annual usage totals approximately 119,875 bottles across two dosage forms, highlighting the importance of these medications in treating Parkinson's disease and related conditions. Interested parties should note that the electronic solicitation is expected to be issued around January 3, 2026, with offers due by January 17, 2026; questions can be directed to the contracting officer, Chris Carthron, at Christopher.Carthron@va.gov.
    Dimethyl Fumarate DR Presolicitation
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.